{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Subcutaneous+Injection&page=38",
    "query": {
      "intervention": "Placebo for Subcutaneous Injection",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 1163,
    "total_pages": 117,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Subcutaneous+Injection&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+Subcutaneous+Injection&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T10:13:41.056Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05722522",
      "title": "Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rotator Cuff Tendinopathy"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2023-08-10",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-11-19T10:13:41.056Z",
      "location_count": 6,
      "location_summary": "Westlake Village, California • Miami, Florida • Plantation, Florida + 3 more",
      "locations": [
        {
          "city": "Westlake Village",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05722522"
    },
    {
      "nct_id": "NCT06687980",
      "title": "A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lichen Simplex Chronicus"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2024-11-25",
      "completion_date": "2026-09-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-11-19T10:13:41.056Z",
      "location_count": 12,
      "location_summary": "Anaheim, California • Fremont, California • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06687980"
    },
    {
      "nct_id": "NCT02098473",
      "title": "Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "RPC4046",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-08-31",
      "completion_date": "2017-01-30",
      "has_results": false,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-11-19T10:13:41.056Z",
      "location_count": 27,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Oceanside, California + 24 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02098473"
    },
    {
      "nct_id": "NCT02405442",
      "title": "Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Andecaliximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 187,
      "start_date": "2015-04-30",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-11-19T10:13:41.056Z",
      "location_count": 33,
      "location_summary": "Dothan, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02405442"
    },
    {
      "nct_id": "NCT00911170",
      "title": "PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer",
        "Colon Cancer",
        "Colorectal Cancer",
        "Fever",
        "Locally Advanced",
        "Metastatic Colorectal Cancer",
        "Neutropenia",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 847,
      "start_date": "2009-11-03",
      "completion_date": "2015-01-02",
      "has_results": true,
      "last_update_posted_date": "2017-12-29",
      "last_synced_at": "2026-11-19T10:13:41.056Z",
      "location_count": 72,
      "location_summary": "Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00911170"
    },
    {
      "nct_id": "NCT02696148",
      "title": "A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolism and Nutrition Disorder",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "7 Years to 11 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-03-14",
      "completion_date": "2017-04-13",
      "has_results": false,
      "last_update_posted_date": "2019-03-18",
      "last_synced_at": "2026-11-19T10:13:41.056Z",
      "location_count": 9,
      "location_summary": "Anaheim, California • New Haven, Connecticut • Jacksonville, Florida + 6 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02696148"
    },
    {
      "nct_id": "NCT07647510",
      "title": "A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myasthenia Gravis, Generalized"
      ],
      "interventions": [
        {
          "name": "Claseprubart",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Claseprubart",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Dianthus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 195,
      "start_date": "2026-06-29",
      "completion_date": "2031-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-19T10:13:41.056Z",
      "location_count": 4,
      "location_summary": "Pasadena, California • Boca Raton, Florida • Fayetteville, North Carolina + 1 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Fayetteville",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07647510"
    },
    {
      "nct_id": "NCT03398135",
      "title": "A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis (UC)"
      ],
      "interventions": [
        {
          "name": "risankizumab",
          "type": "DRUG"
        },
        {
          "name": "placebo for risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "16 Years to 80 Years"
      },
      "enrollment_count": 1242,
      "start_date": "2018-08-28",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-11-19T10:13:41.056Z",
      "location_count": 78,
      "location_summary": "Coronado, California • Irvine, California • La Jolla, California + 60 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03398135"
    },
    {
      "nct_id": "NCT03246529",
      "title": "A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "BL-8040 1.25 mg/kg + G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Placebo +G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioLineRx, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "18 Years to 78 Years"
      },
      "enrollment_count": 180,
      "start_date": "2018-03-23",
      "completion_date": "2029-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-11-19T10:13:41.056Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03246529"
    },
    {
      "nct_id": "NCT02501629",
      "title": "An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma",
        "Elevated Blood Eosinophils",
        "Oral Corticosteroid Dependence"
      ],
      "interventions": [
        {
          "name": "Reslizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Non-Oral Corticosteroid (non-OCS) Asthma Medication",
          "type": "DRUG"
        },
        {
          "name": "Oral Corticosteroid (OCS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2015-09-29",
      "completion_date": "2017-12-04",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-11-19T10:13:41.056Z",
      "location_count": 26,
      "location_summary": "Bakersfield, California • Long Beach, California • Clermont, Florida + 21 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Clermont",
          "state": "Florida"
        },
        {
          "city": "Homestead",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02501629"
    }
  ]
}